FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1488703195> ?p ?o ?g. }

• W1488703195 endingPage "446" @default.
• W1488703195 startingPage "442" @default.
• W1488703195 abstract "We evaluated the efficacy, safety and tolerability of etravirine in paediatric patients vertically infected with HIV-1.A multicentre retrospective study of 23 multidrug-resistant paediatric patients (five children and 18 adolescents) enrolled in the study from 1 September 2007 to 28 February 2010 was carried out. We performed a longitudinal analysis of immunological, virological and clinical data.The median age of the patients was 14.2 years [interquartile range (IQR) 12.5-15.8 years]. At baseline, the median HIV-1 RNA was 29 000 (4.5 log(10) ) HIV-1 RNA copies/mL (range 4300-83 000 copies/mL), the median CD4 T-cell count was 445 cells/μL (range 221-655 cells/μL) and the median CD4 percentage was 19.6% (IQR 13.0-31.0). Remarkably, 16 of 23 patients (70%) harboured one or more etravirine-associated resistance mutations. The backbone regimen included at least two fully active drugs in 91% of patients. After etravirine-based therapy, 20 patients (87%) achieved HIV-1 RNA<400 copies/mL and 18 of 23 (78%) achieved HIV-1 RNA<50 copies/mL: three (13%) within the first month, seven (30%) within the first 4 months, and six (26%) between the 5th and 8th months. CD4 T-cell recovery was observed in 19 patients (83%). The median follow-up time was 48.4 weeks (IQR 35.7-63.4 weeks); four patients (17%) were exposed to etravirine for >120 weeks. Three mild/short-term and two moderate skin rashes were observed in the adolescents. Laboratory abnormalities included hypercholesterolaemia (11 of 23 patients), hypertriglyceridaemia (eight of 23 patients), and reduced high-density lipoprotein cholesterol (10 of 23 patients). Adherence was complete in seven patients (30%). No patients showed complete resistance to etravirine after follow-up. However, three of 21 patients (14%) who initially showed intermediate resistance interrupted etravirine treatment because of virological failure.We observed a sustained antiviral response and improved immunological parameters in multidrug-resistant paediatric patients, most of whom had received etravirine as part of salvage regimens with at least two fully active drugs." @default.
• W1488703195 created "2016-06-24" @default.
• W1488703195 creator A5002321252 @default.
• W1488703195 creator A5002398755 @default.
• W1488703195 creator A5006861309 @default.
• W1488703195 creator A5015526782 @default.
• W1488703195 creator A5030366995 @default.
• W1488703195 creator A5049601897 @default.
• W1488703195 creator A5057030885 @default.
• W1488703195 creator A5060947757 @default.
• W1488703195 creator A5061152224 @default.
• W1488703195 creator A5063394105 @default.
• W1488703195 date "2011-03-13" @default.
• W1488703195 modified "2023-10-14" @default.
• W1488703195 title "Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients" @default.
• W1488703195 cites W1996967038 @default.
• W1488703195 cites W2075743172 @default.
• W1488703195 cites W2135113708 @default.
• W1488703195 doi "https://doi.org/10.1111/j.1468-1293.2010.00907.x" @default.
• W1488703195 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21395964" @default.
• W1488703195 hasPublicationYear "2011" @default.
• W1488703195 type Work @default.
• W1488703195 sameAs 1488703195 @default.
• W1488703195 citedByCount "20" @default.
• W1488703195 countsByYear W14887031952012 @default.
• W1488703195 countsByYear W14887031952013 @default.
• W1488703195 countsByYear W14887031952015 @default.
• W1488703195 countsByYear W14887031952017 @default.
• W1488703195 countsByYear W14887031952018 @default.
• W1488703195 countsByYear W14887031952019 @default.
• W1488703195 countsByYear W14887031952020 @default.
• W1488703195 countsByYear W14887031952022 @default.
• W1488703195 crossrefType "journal-article" @default.
• W1488703195 hasAuthorship W1488703195A5002321252 @default.
• W1488703195 hasAuthorship W1488703195A5002398755 @default.
• W1488703195 hasAuthorship W1488703195A5006861309 @default.
• W1488703195 hasAuthorship W1488703195A5015526782 @default.
• W1488703195 hasAuthorship W1488703195A5030366995 @default.
• W1488703195 hasAuthorship W1488703195A5049601897 @default.
• W1488703195 hasAuthorship W1488703195A5057030885 @default.
• W1488703195 hasAuthorship W1488703195A5060947757 @default.
• W1488703195 hasAuthorship W1488703195A5061152224 @default.
• W1488703195 hasAuthorship W1488703195A5063394105 @default.
• W1488703195 hasBestOaLocation W14887031951 @default.
• W1488703195 hasConcept C119060515 @default.
• W1488703195 hasConcept C126322002 @default.
• W1488703195 hasConcept C142462285 @default.
• W1488703195 hasConcept C167135981 @default.
• W1488703195 hasConcept C197934379 @default.
• W1488703195 hasConcept C203014093 @default.
• W1488703195 hasConcept C2778375690 @default.
• W1488703195 hasConcept C2780345285 @default.
• W1488703195 hasConcept C2781413609 @default.
• W1488703195 hasConcept C2993143319 @default.
• W1488703195 hasConcept C3013748606 @default.
• W1488703195 hasConcept C71924100 @default.
• W1488703195 hasConcept C90924648 @default.
• W1488703195 hasConceptScore W1488703195C119060515 @default.
• W1488703195 hasConceptScore W1488703195C126322002 @default.
• W1488703195 hasConceptScore W1488703195C142462285 @default.
• W1488703195 hasConceptScore W1488703195C167135981 @default.
• W1488703195 hasConceptScore W1488703195C197934379 @default.
• W1488703195 hasConceptScore W1488703195C203014093 @default.
• W1488703195 hasConceptScore W1488703195C2778375690 @default.
• W1488703195 hasConceptScore W1488703195C2780345285 @default.
• W1488703195 hasConceptScore W1488703195C2781413609 @default.
• W1488703195 hasConceptScore W1488703195C2993143319 @default.
• W1488703195 hasConceptScore W1488703195C3013748606 @default.
• W1488703195 hasConceptScore W1488703195C71924100 @default.
• W1488703195 hasConceptScore W1488703195C90924648 @default.
• W1488703195 hasIssue "7" @default.
• W1488703195 hasLocation W14887031951 @default.
• W1488703195 hasLocation W14887031952 @default.
• W1488703195 hasOpenAccess W1488703195 @default.
• W1488703195 hasPrimaryLocation W14887031951 @default.
• W1488703195 hasRelatedWork W1912089629 @default.
• W1488703195 hasRelatedWork W1970975200 @default.
• W1488703195 hasRelatedWork W1987278538 @default.
• W1488703195 hasRelatedWork W2001009580 @default.
• W1488703195 hasRelatedWork W2106352067 @default.
• W1488703195 hasRelatedWork W2409851437 @default.
• W1488703195 hasRelatedWork W2506942807 @default.
• W1488703195 hasRelatedWork W3116631328 @default.
• W1488703195 hasRelatedWork W3159473083 @default.
• W1488703195 hasRelatedWork W4298619699 @default.
• W1488703195 hasVolume "12" @default.
• W1488703195 isParatext "false" @default.
• W1488703195 isRetracted "false" @default.
• W1488703195 magId "1488703195" @default.
• W1488703195 workType "article" @default.